Ipsen S.A (I7G) - Total Liabilities
Based on the latest financial reports, Ipsen S.A (I7G) has total liabilities worth €2.60 Billion EUR as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Ipsen S.A - Total Liabilities Trend (2013–2024)
This chart illustrates how Ipsen S.A's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Ipsen S.A Competitors by Total Liabilities
The table below lists competitors of Ipsen S.A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Neste Oyj
F:NEF
|
Germany | €8.33 Billion |
|
First Financial Holding Co Ltd
TW:2892
|
Taiwan | NT$4.64 Trillion |
|
CNA Financial Corporation
NYSE:CNA
|
USA | $58.43 Billion |
|
Scentre Group
AU:SCG
|
Australia | AU$16.32 Billion |
|
Penumbra Inc
NYSE:PEN
|
USA | $385.67 Million |
|
Neurocrine Biosciences Inc
NASDAQ:NBIX
|
USA | $1.38 Billion |
|
Impala Platinum Holdings Ltd
JSE:IMP
|
South Africa | ZAC39.24 Billion |
|
Sterling Construction Company Inc
NASDAQ:STRL
|
USA | $1.53 Billion |
Liability Composition Analysis (2013–2024)
This chart breaks down Ipsen S.A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.98 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.61 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ipsen S.A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ipsen S.A (2013–2024)
The table below shows the annual total liabilities of Ipsen S.A from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €2.26 Billion | -9.68% |
| 2023-12-31 | €2.50 Billion | +10.03% |
| 2022-12-31 | €2.27 Billion | +0.82% |
| 2021-12-31 | €2.25 Billion | +2.61% |
| 2020-12-31 | €2.20 Billion | -14.04% |
| 2019-12-31 | €2.55 Billion | +66.49% |
| 2018-12-31 | €1.53 Billion | -0.14% |
| 2017-12-31 | €1.54 Billion | +44.74% |
| 2016-12-31 | €1.06 Billion | +48.98% |
| 2015-12-31 | €712.40 Million | +10.38% |
| 2014-12-31 | €645.40 Million | +9.09% |
| 2013-12-31 | €591.60 Million | -- |
About Ipsen S.A
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injec… Read more